The effectiveness of glucocorticoid combined with terbutaline in the treatment of chronic obstructive pulmonary disease

 COPD, the full name of chronic obstructive pulmonary disease, is a respiratory disease. COPD can block the airflow when the patient breathes and is irreversible, causing respiratory failure and threatening the life of the patient. Medication with glucocorticoids alone cannot effectively relieve the clinical symptoms of COPD. Terbutaline can effectively expand the bronchi, reduce airflow obstruction, and relieve a series of clinical symptoms caused by COPD [1]. Therefore, this article takes 80 patients with chronic obstructive pulmonary disease admitted to our hospital from January 2018 to January 2020. The treatment with glucocorticoid combined with terbutaline has achieved relatively significant results. The report is as follows:
  1 Data and methods
  1.1 general information
  select January 2018 – a total of 80 cases of patients with chronic obstructive pulmonary disease in January 2020 in our hospital, according to the drug were divided into study group and control group, 40 cases in each group. Among them, there were 22 males and 18 females in the study group, aged 51-67 years old, with an average of (59.3±4.6) years; 25 males and 15 females in the control group, aged 53-69 years, with an average of (61.2±3.5) years old. The basic data (P>0.05) of the two groups of patients were comparable. All patients and their families were aware of this study and signed a consent form.
  in the control group were treated with terbutaline aerosol therapy, 1mL / times, 15 ~ 20min / times, 2 times / d morning and evening, 30d continuous treatment
  study patients administering glucocorticoid therapy terbutaline, selection Mometasone furoate suspension 100ug/time, 2 times/d, 15~20min/time combined with terbutaline (dose same as control group) for nebulization treatment, continuous treatment for 30d
  1.3 Observation index
  Therapeutic effect: markedly effective: the patient’s condition recovers, the symptoms such as cough, chest tightness and dyspnea disappear completely, and all indicators return to normal; effective: the patient’s condition basically recovered, the symptoms such as cough, chest tightness and dyspnea are not obvious, and the indicators are close to normal Invalid: The patient’s condition has not improved significantly, and the symptoms such as cough, chest tightness and dyspnea have not improved, and even worsened.
  1.4 statistical methods
  in this study were all data analysis software application SPSS22.0, measurement data () represents, t-test; count data of said line test; P <0.05 represents statistically significant.   Results 2   treatment groups were 2.1 Comparative   after treatment, the total efficiency of the control group (75.00%), the total efficiency of the study group (97.50%) have significantly increased, the difference was statistically significant (P <0.05). See Table 1 for details.   2.2 two groups of patients blood indicators Comparative   Comparative Comparative indicators two blood before and after treatment before treatment, the study group of patients with blood oxygen partial pressure (PaO2), carbon dioxide partial pressure (PaCO2) no significant difference between control group (P >0.05). After treatment, the PaO2 and PaCO2 values ​​of the study group were significantly lower than those of the control group (P<0.05), and the PaO2 value was significantly increased (P<0.05). See Table 2 for details.   3 Discussion   of COPD patients were treated with antibiotics drugs in clinical, terbutaline is a common therapeutic agent, drug major role in the bronchi of the patient, the patient can effectively expand the bronchi, reducing the number of bronchial smooth muscle spasm, Thereby reducing the phenomenon of airflow obstruction in patients [3-4]. Glucocorticoids are anti-airway inflammation drugs with a wide range of clinical applications. They can inhibit the production and release of inflammatory substances, reduce the permeability of the capillaries in the patient’s airways, improve lung function, and have a strong anti-airway function. Inflammation [5]. Therefore, the combination of glucocorticoid and terbutaline in the treatment of chronic obstructive pulmonary disease can not only reduce the symptoms of adverse reactions, but also greatly improve the therapeutic effect, which is favored by physicians. The results of this study show that glucocorticoid combined with terbutaline has a good therapeutic effect on the treatment of COPD.   In summary, glucocorticoids can effectively improve the symptoms of COPD patients, and treatment with terbutaline can reduce the patient’s dyspnea frequency, restore the patient’s various qi and blood indicators, and improve the therapeutic effect. The safety is also guaranteed, and it has better High clinical application promotion value.